U.S. Third-Party Medicines

U.S. Audiences

All product information provided on this page is intended for U.S. audiences only. The medicines listed below may not be available in countries outside the U.S. or may be available under a different trademark name, in different strengths, or for different indications. Countries outside the U.S. may have different regulatory and labeling requirements that would call for different information to be made available with respect to these medicines.

Licensed U.S. Medicines

We have licensed medicines to third parties for commercialization, for which we receive royalties and/or manufacturing revenues. Such arrangements in the U.S. include the following:

VUMERITY^® (diroximel fumarate)

Prescribing Information

For more information, please visit Biogen's website

U.S. Medicines Using Alkermes' Technologies

We have granted licenses under our proprietary technologies to enable third parties to develop, commercialize and, in some cases, manufacture medicines for which we receive royalties and/or manufacturing revenues. Such arrangements in the U.S. include the following:

RISPERDAL CONSTA^® (risperidone)
LONG-ACTING INJECTION

Prescribing Information including BOXED WARNING

For more information, please visit Janssen's website

INVEGA SUSTENNA^® (paliperidone palmitate)

Prescribing Information including BOXED WARNING

For more information, please visit Janssen's website

INVEGA TRINZA^® (paliperidone palmitate)

Prescribing Information including BOXED WARNING

For more information, please visit Janssen's website

INVEGA HAFYERA^® (paliperidone palmitate)

Prescribing Information including BOXED WARNING

For more information, please visit Janssen's website

VUMERITY^® is a registered trademark of Biogen MA Inc, used by Alkermes under license. RISPERDAL CONSTA^®, INVEGA SUSTENNA^®, INVEGA TRINZA^® and INVEGA HAFYERA^® are registered trademarks of Johnson & Johnson Corporation.

This page is intended for U.S. audiences only.